Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
Abstract The standard of care for patients with locoregionally advanced nasopharyngeal carcinoma is concurrent platinum-based chemoradiotherapy. Existing literature have demonstrated that the addition of gemcitabine and cisplatin as induction chemotherapy in locoregionally advanced nasopharyngeal ca...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-06-01
|
Series: | Cancer Communications |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40880-019-0385-5 |
id |
doaj-60e52cc99fd64e31bb0cb0124cd48de2 |
---|---|
record_format |
Article |
spelling |
doaj-60e52cc99fd64e31bb0cb0124cd48de22020-11-25T03:05:37ZengWileyCancer Communications2523-35482019-06-013911410.1186/s40880-019-0385-5Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinomaYuan Zhang0Ying Sun1Jun Ma2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and TherapyDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and TherapyDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and TherapyAbstract The standard of care for patients with locoregionally advanced nasopharyngeal carcinoma is concurrent platinum-based chemoradiotherapy. Existing literature have demonstrated that the addition of gemcitabine and cisplatin as induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma may have promising efficacy but were from phase 2 clinical trials. Stronger evidence-based data in forms of phase 3 clinical trial investigating the survival benefits of adding gemcitabine and cisplatin induction chemotherapy for such patients have been urgently warranted. In one of our recent studies published in the New England Journal of Medicine, “Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma”, 480 locoregionally advanced nasopharyngeal carcinoma patients from 12 hospitals across China were randomly assigned in a 1:1 ratio to receive either chemoradiotherapy alone or gemcitabine plus cisplatin and chemoradiotherapy. Our findings evinced that, as compared to chemoradiotherapy alone, the addition of induction chemotherapy comprising of gemcitabine plus cisplatin to concurrent cisplatin-radiotherapy to patients with locoregionally advanced nasopharyngeal carcinoma was safe, demonstrated improved recurrence-free survival, overall survival, and distant recurrence-free survival, and marginally superior locoregional recurrence-free survival.http://link.springer.com/article/10.1186/s40880-019-0385-5GemcitabineCisplatinInduction chemotherapyNasopharyngeal carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuan Zhang Ying Sun Jun Ma |
spellingShingle |
Yuan Zhang Ying Sun Jun Ma Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma Cancer Communications Gemcitabine Cisplatin Induction chemotherapy Nasopharyngeal carcinoma |
author_facet |
Yuan Zhang Ying Sun Jun Ma |
author_sort |
Yuan Zhang |
title |
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma |
title_short |
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma |
title_full |
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma |
title_fullStr |
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma |
title_full_unstemmed |
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma |
title_sort |
induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma |
publisher |
Wiley |
series |
Cancer Communications |
issn |
2523-3548 |
publishDate |
2019-06-01 |
description |
Abstract The standard of care for patients with locoregionally advanced nasopharyngeal carcinoma is concurrent platinum-based chemoradiotherapy. Existing literature have demonstrated that the addition of gemcitabine and cisplatin as induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma may have promising efficacy but were from phase 2 clinical trials. Stronger evidence-based data in forms of phase 3 clinical trial investigating the survival benefits of adding gemcitabine and cisplatin induction chemotherapy for such patients have been urgently warranted. In one of our recent studies published in the New England Journal of Medicine, “Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma”, 480 locoregionally advanced nasopharyngeal carcinoma patients from 12 hospitals across China were randomly assigned in a 1:1 ratio to receive either chemoradiotherapy alone or gemcitabine plus cisplatin and chemoradiotherapy. Our findings evinced that, as compared to chemoradiotherapy alone, the addition of induction chemotherapy comprising of gemcitabine plus cisplatin to concurrent cisplatin-radiotherapy to patients with locoregionally advanced nasopharyngeal carcinoma was safe, demonstrated improved recurrence-free survival, overall survival, and distant recurrence-free survival, and marginally superior locoregional recurrence-free survival. |
topic |
Gemcitabine Cisplatin Induction chemotherapy Nasopharyngeal carcinoma |
url |
http://link.springer.com/article/10.1186/s40880-019-0385-5 |
work_keys_str_mv |
AT yuanzhang inductiongemcitabineandcisplatininlocoregionallyadvancednasopharyngealcarcinoma AT yingsun inductiongemcitabineandcisplatininlocoregionallyadvancednasopharyngealcarcinoma AT junma inductiongemcitabineandcisplatininlocoregionallyadvancednasopharyngealcarcinoma |
_version_ |
1724677574953533440 |